Mary Beth DeLena

City Therapeutics, Inc. (City), a clinical-stage biotechnology company developing next-generation RNA interference (RNAi) therapeutics, has appointed Keith Regnante, MBA, as Chief Financial Officer and Mary Beth DeLena, J.D., as Chief Legal Officer.

DeLena brings more than 25 years of legal and corporate experience across the life sciences industry, spanning early-stage research and development through commercial launch.

She joins City from Paragon Therapeutics, where she served as Chief Legal Officer with responsibility for corporate governance, licensing, alliance management and intellectual property. Previously, she served as General Counsel and Secretary of PepGen Inc.

DeLena spent more than 15 years at Alnylam Pharmaceuticals, most recently serving as Senior Vice President, Deputy General Counsel and Assistant Secretary. During her tenure, the company advanced five RNAi therapeutics toward FDA approval. She also advised senior leadership on several major strategic transactions, including a $2 billion strategic financing collaboration with Blackstone, an $800 million eye and CNS collaboration with Regeneron and a $700 million rare disease collaboration with Sanofi Genzyme.

Earlier in her career, DeLena served as Vice President, Legal and Secretary at Praecis Pharmaceuticals and began her legal career at Skadden, Arps, Slate, Meagher & Flom LLP.
She earned a J.D. from Northeastern University School of Law and a bachelor’s degree in English from Trinity College.

The appointments strengthen City Therapeutics’ financial and legal leadership as the company advances its next-generation RNAi platform and expands its clinical-stage pipeline.